Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
RxSight, Inc. (RXST)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
8-K
| Quarterly results|
Docs:
|
"RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Sales $ 20,810 $ 11,360 $ 38,299 $ 20,301 Cost of sales 8,795 6,572 15,919 11,752 Gross profit 12,015 4,788 22,380 8,549 Operating expenses: Selling, general and administrative 18,239 14,388 34,492 28,008 Research and development 7,401 6,192 14,608 12,911 Total operating expenses 25,640 20,580 49,100 40,919 Loss from operations Other income , net: Interest expense Interest and other income 1,777 196 3,168 242 Loss on extinguishment of term loan — — Loss before income taxes Income tax expense 26 — 27 4 Net loss $ $ $ $ Other comprehensive income Unrealized gain on short-term investments 19 Foreign currency translation gain 1 3..." |
|
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended March 31, 2023 2022 Sales $ 17,489 $ 8,942 Cost of sales 7,123 5,181 Gross profit 10,366 3,761 Operating expenses: Selling, general and administrative 16,255 13,620 Research and development 7,208 6,719 Total operating expenses 23,463 20,339 Loss from operations Other income , net: Interest expense Interest and other income 1,392 46 Loss before income taxes Income tax expense — 4 Net loss $ $ Other comprehensive income Unrealized gain on short-term investments 84 Foreign currency translation gain 2 Total other comprehensive income 86 Comprehensive loss $ $ Net loss per share: Basic & diluted $ $ Weighted-average shares used in computing net loss per share: Attributable to common stock..." |
|
| 11/07/2022 |
8-K
| Quarterly results|
Docs:
|
"RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Sales $ 12,615 $ 5,786 $ 32,917 $ 14,167 Cost of sales 7,259 4,445 19,011 12,519 Gross profit 5,356 1,341 13,906 1,648 Operating expenses: Selling, general and administrative 14,926 9,076 42,934 21,189 Research and development 6,388 5,377 19,300 18,583 Total operating expenses 21,314 14,453 62,234 39,772 Loss from operations Other income , net: Change in fair value of warrants — 1,503 — 2,717 Expiration of warrant — — — 5,018 Interest expense Interest and other income 439 11 681 44 Loss before income taxes Income tax expense — 4 6 Net loss $ $ $ $ Other comprehensive loss Unrealized gain on short-term investments 55..." |
|
| 08/08/2022 |
8-K
| Quarterly results|
Docs:
|
"RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Sales $ 11,360 $ 4,897 $ 20,301 $ 8,381 Cost of sales 6,572 5,709 11,752 8,074 Gross profit 4,788 8,549 307 Operating expenses: Selling, general and administrative 14,388 6,502 28,008 12,113 Research and development 6,192 6,563 12,911 13,206 Total operating expenses 20,580 13,065 40,919 25,319 Loss from operations Other income , net: Change in fair value of warrants — 1,214 — 1,214 Expiration of warrant — — — 5,018 Interest expense Interest and other income 196 15 242 32 Loss before income taxes Income tax expense 0 3 4 10 Net loss $ $ $ $ Other comprehensive loss Unrealized gain on short-term investments 3 Foreign currency t..." |
|
| 05/05/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Sales $ 5,786 $ 4,170 $ 14,167 $ 9,764 Cost of sales 4,445 3,450 12,519 9,439 Gross profit 1,341 720 1,648 325 Operating expenses: Selling, general and administrative 9,076 3,825 21,189 10,773 Research and development 5,377 5,801 18,583 16,662 Total operating expenses 14,453 9,626 39,772 27,435 Loss from operations Other income , net: Change in fair value of warrants 1,503 39,518 2,717 27,933 Expiration of warrant — — 5,018 — Interest expense Interest and other income 11 63 44 522 income before income taxes 30,672 1,333 Income tax expense 8 6 53 Net income 30,664 1,280 Accretion to redemption value of redeemable pre..." |
|
| 09/09/2021 |
8-K
| Quarterly results |
|
|